Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 1.27 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 4:00pm Bid x Ask Size: N/A
Change: down arrow -0.0100 (-0.78%) Day's Range: 1.26 - 1.33
Prev Close: 1.2800 52wk Range: 0.53 - 3.10
Open: 1.2800 P/E (ttm): N/A
Volume: 1,324,869 EPS (ttm): -0.624
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Fri, 18 Apr 2014 10:02:06 GMT
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million
Thu, 17 Apr 2014 15:55:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock.
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Tue, 15 Apr 2014 10:01:04 GMT
CEL-SCI Corporation Prices $10 Million Public Offering of Common Stock and Six Month Warrants
Mon, 14 Apr 2014 13:10:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it has priced a “best efforts” underwritten public offering of units of common stock and warrants at a price of $1.40 per unit for gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses of the Company.
CEL SCI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mon, 14 Apr 2014 10:02:16 GMT
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
Fri, 11 Apr 2014 20:15:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it intends to offer and sell common stock and six month warrants in a “best efforts” underwritten public offering.
CEL-SCI requests withdrawal of registration statement
Thu, 10 Apr 2014 15:53:06 GMT
Henry Ford Health System of Detroit to Enroll and Treat Patients in CEL-SCI’s Phase III Head and Neck Cancer Clinical Trial
Tue, 08 Apr 2014 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the Henry Ford Health System in Detroit, Michigan is the latest U.S. clinical center to join the Company’s Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* .
Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial
Wed, 02 Apr 2014 15:39:36 GMT
CEL-SCI expands Multikine Phase III Head, Neck Cancer clinical trial
Wed, 02 Apr 2014 12:08:20 GMT
Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI’s Global Phase III Head and Neck Cancer Trial
Wed, 02 Apr 2014 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced it has expanded its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* in the U.S.
CEL-SCI enrolled 14 patients in March into Phase III head and neck cancer trial
Tue, 01 Apr 2014 12:31:35 GMT
CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial
Tue, 01 Apr 2014 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of March the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial.
CEL-SCI Corporation (CVM): Significant Potential, but a Long Way from Results
Thu, 27 Mar 2014 11:30:00 GMT
[PR Newswire] - NEW YORK, March 27, 2014 /PRNewswire/ -- Across the globe, there are over 13 million new cancer cases each year. By 2030, it is estimated by the International Agency for Research on Cancer (IARC) that there will be approximately 21.4 million new cancer cases and 13.2 million cancer deaths worldwide. Some of the more common (and deadly) forms of cancer are head and neck cancer, which account for approximately 600,000 new cases worldwide each year and result in a five-year survival rate of around 30%. One company that is actively trying to fight this disease is CEL-SCI Corporation (CVM).
CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio
Tue, 25 Mar 2014 14:26:09 GMT
[Marketwired] - CEL-SCI Corporation , a leading research and development company dedicated to improving the treatment of cancer and other diseases by utilizing the immune system, today announced that CEO Geert Kersten ...
Insider Buying Is On The Rise In These 4 Rallying Stocks
Thu, 20 Mar 2014 22:16:00 GMT
Cel-Sci's Multikine - Potential 21st Century Superdrug
Thu, 13 Mar 2014 21:41:33 GMT
NEW STORY First U.S. Clinical Site Opens for CEL-SCI'S Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion
Tue, 04 Mar 2014 15:40:16 GMT
[at noodls] - FIRST U.S. CLINICAL SITE OPENS FOR CEL-SCI'S GLOBAL PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL EXPANSION 10 to 15 U.S. centers planned for American cancer patients to enroll in the world's largest ...
First U.S. Clinical Site Opens for CEL-SCI’s Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion
Tue, 04 Mar 2014 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* has activated its first U.S.
CEL-SCI Reports 146 Patients Enrolled in Its Phase III Immunotherapy Head and Neck Cancer Trial
Thu, 27 Feb 2014 14:00:00 GMT
[Business Wire] - CEL-SCI Corporation today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* .